Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NasdaqGM:NAMS
NasdaqGM:NAMSBiotechs

Should NewAmsterdam’s Multi-Indication Obicetrapib Strategy Reshape How NAMS Investors View Pipeline Concentration?

NewAmsterdam Pharma recently outlined its late-stage plans for obicetrapib, including an expected EMA approval decision in the second half of 2026, first-patient dosing in the RUBENS Phase 3 metabolic syndrome trial, continued progress in the PREVAIL cardiovascular outcomes study, and preparations for an Alzheimer’s disease trial based on earlier biomarker data. These updates give investors clearer visibility into NewAmsterdam’s pipeline evolution across cardiometabolic and neurological...
NasdaqGS:LENZ
NasdaqGS:LENZPharmaceuticals

Does LENZ Therapeutics' (LENZ) VIZZ Middle East Deal Reframe Its Global Ophthalmology Ambitions?

LENZ Therapeutics and Lunatus Marketing & Consulting FZCO recently announced an exclusive agreement for Lunatus to register and commercialize VIZZ, an FDA-approved aceclidine-based eye drop for presbyopia, across multiple Middle East markets including the UAE, Saudi Arabia and Qatar. The deal builds on VIZZ’s early U.S. launch, where the product generated about US$1.6 million in Q4 2025 revenue from over 20,000 prescriptions and broad uptake by eye care professionals. We’ll explore how early...